CVS Health 8-K Hints at Financials, Officer Changes, Reg FD Disclosure

Ticker: CVS · Form: 8-K · Filed: 2024-01-05T00:00:00.000Z

Sentiment: mixed

Topics: financial-condition, officer-changes, regulation-fd

TL;DR

**CVS filed an 8-K, likely signaling upcoming news on financials or leadership changes.**

AI Summary

CVS Health Corp filed an 8-K on January 5, 2024, indicating that it is reporting on "Results of Operations and Financial Condition," "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers," and "Regulation FD Disclosure." This filing suggests that CVS may be providing an update on its financial performance, changes in its executive team or board, and potentially disclosing material non-public information. For investors, this matters because it could signal upcoming financial results, strategic shifts, or leadership changes that could impact the company's future direction and stock price.

Why It Matters

This filing signals potential upcoming news regarding CVS Health's financial performance, executive leadership, or other material information, which could directly influence investor sentiment and stock valuation.

Risk Assessment

Risk Level: medium — The filing indicates potential significant news without providing specifics, creating uncertainty about the nature and impact of the disclosed information.

Analyst Insight

A smart investor would monitor CVS Health's news releases closely in the coming days for specific details on financial performance, executive changes, or any Regulation FD disclosures, as these could significantly impact the stock.

Key Players & Entities

Forward-Looking Statements

FAQ

What specific items are being reported in this 8-K filing by CVS Health Corp?

CVS Health Corp is reporting on "Results of Operations and Financial Condition," "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers," and "Regulation FD Disclosure" as per the ITEM INFORMATION section of the filing.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 5, 2024, as stated in the filing.

Where is CVS Health Corporation's principal executive office located?

CVS Health Corporation's principal executive office is located at One CVS Drive, Woonsocket, Rhode Island 02895, according to the filing's business address.

What is the telephone number for CVS Health Corporation?

The registrant's telephone number, including area code, is (401) 765-1500, as provided in the filing.

Under which SEC Act is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934, as indicated in the filing.

From the Filing

0000947871-24-000009.txt : 20240105 0000947871-24-000009.hdr.sgml : 20240105 20240105064114 ACCESSION NUMBER: 0000947871-24-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 24514408 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 ss2874786_8k.htm CURRENT REPORT false 0000064803 false false false false 0000064803 2024-01-05 2024-01-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 5, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)         One CVS Drive , Woonsocket , Rhode Island 		 02895 (Address of principal executive offices)		(Zip Code)   Registrant’s telephone number, including area code: 		 ( 401 ) 765-1500 Former name or former address, if changed since last report:	 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share CVS New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐               Item 2.02 Results of Operations and Financial Condition.   On January 8, 2024, members of the senior management team of CVS Health Corporation (“CVS Health,” the “Company,” “we” or “our”) will meet

View on Read The Filing